Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors
- PMID: 31451969
- DOI: 10.1007/164_2019_265
Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors
Abstract
Despite the therapeutic utility of opioids for relieving pain, other behavioral effects, including their potential for abuse and overdose, can be quite detrimental to individuals as well as society and have contributed to the ongoing opioid crisis. The dramatic escalation in overdose deaths over the last 15 years was initially driven by abuse of prescription opioids, although abuse of heroin, fentanyl, and fentanyl analogs has been increasing, largely due to increased availability and lower cost compared with prescription opioids. All of these opioids share pharmacological properties, acting as agonists at mu opioid receptors, and produce similar behavioral effects, including abuse-related, pain-relieving, dependence-producing, and respiratory-depressant effects. Despite their similarities, opioids are not pharmacologically identical. In fact, drugs that act at mu opioid receptors, including abused opioids, can vary on a number of dimensions, including pharmacological efficacy, drug-receptor interactions, receptor selectivity, and pharmacokinetics. Overall, these differences impact behavioral effects of drugs acting at mu opioid receptors, and this chapter describes variations in those behavioral effects and how these differences continue to provide new strategies that can be developed to address the ongoing opioid epidemic.
Keywords: Behavioral pharmacology; Drug-receptor interactions; Efficacy; Mu opioid receptors; Opioid abuse; Treatments.
Similar articles
-
Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic.Pain Physician. 2018 Jul;21(4):309-326. Pain Physician. 2018. PMID: 30045589
-
Replacement of current opioid drugs focusing on MOR-related strategies.Pharmacol Ther. 2020 Jun;210:107519. doi: 10.1016/j.pharmthera.2020.107519. Epub 2020 Mar 9. Pharmacol Ther. 2020. PMID: 32165137 Review.
-
Characterization of the Discriminative Stimulus Effects of Binary Mixtures of Mu Opioid Receptor Agonists in Rats Discriminating Fentanyl.J Pharmacol Exp Ther. 2022 Mar;380(3):171-179. doi: 10.1124/jpet.121.000912. Epub 2021 Dec 13. J Pharmacol Exp Ther. 2022. PMID: 34903563
-
Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.Cell Mol Neurobiol. 2021 Jul;41(5):899-926. doi: 10.1007/s10571-020-01013-y. Epub 2020 Nov 27. Cell Mol Neurobiol. 2021. PMID: 33245509 Free PMC article. Review.
-
The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.Curr Top Behav Neurosci. 2017;34:33-58. doi: 10.1007/7854_2016_448. Curr Top Behav Neurosci. 2017. PMID: 27356522 Review.
Cited by
-
Recent Increase in Methamphetamine Use in a Cohort of Rural People Who Use Drugs: Further Evidence for the Emergence of Twin Epidemics.Front Psychiatry. 2022 Jan 7;12:805002. doi: 10.3389/fpsyt.2021.805002. eCollection 2021. Front Psychiatry. 2022. PMID: 35069295 Free PMC article.
-
Factors mediating pain-related risk for opioid use disorder.Neuropharmacology. 2021 Mar 15;186:108476. doi: 10.1016/j.neuropharm.2021.108476. Epub 2021 Jan 30. Neuropharmacology. 2021. PMID: 33524407 Free PMC article. Review.
-
Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder.J Exp Anal Behav. 2023 Mar;119(2):392-406. doi: 10.1002/jeab.831. Epub 2023 Feb 9. J Exp Anal Behav. 2023. PMID: 36759567 Free PMC article.
-
Chemogenetics drives paradigm change in the investigation of behavioral circuits and neural mechanisms underlying drug action.Behav Brain Res. 2021 May 21;406:113234. doi: 10.1016/j.bbr.2021.113234. Epub 2021 Mar 16. Behav Brain Res. 2021. PMID: 33741409 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials